Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113522 | 0.85 | ALDH1A1 (0.61) | ALDH1A1MAPTPOLBKMT2ADHFR | |
| SCHEMBL7692901 | 0.84 | ALDH1A1 (0.66) | EGFRALDH1A1POLBKMT2ADHFR | |
| SCHEMBL7694652 | 0.82 | DHFR (0.63) | EGFRALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL7690576 | 0.77 | DHFR (0.76) | ALDH1A1MAPTPOLBKMT2ADHFR | |
| SCHEMBL14164070 | 0.74 | DHFR (0.79) | ALDH1A1MAPTDHFRALOX12HTT | |
| SCHEMBL7695774 | 0.74 | CA1 (0.70) | ALDH1A1MAPTPOLBKMT2ADHFR | |
| SCHEMBL14164069 | 0.74 | DHFR (0.66) | ALDH1A1MAPTDHFRALOX12HTT | |
| SCHEMBL29793883 | 0.73 | DHFR (0.59) | ALDH1A1MAPTPOLBKMT2ADHFR | |
| SCHEMBL10113026 | 0.73 | DHFR (0.62) | EGFRALDH1A1MAPTDHFRALOX12 | |
| SCHEMBL29794007 | 0.73 | DHFR (0.59) | ALDH1A1POLBKMT2ADHFRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | EGFR 4353/4885ALDH1A1 2125/4885MAPT 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.